不同组织学类型分化型甲状腺癌远处转移的摄碘亲和力与放射碘治疗结局
该回顾性研究纳入2001至2018年因远处转移接受放射碘治疗的126例分化型甲状腺癌患者,分析组织学类型与摄碘亲和力及治疗反应的关系。结果发现摄碘亲和力与组织学类型独立相关(P < .001),Hürthle细胞癌最低(13.6%),滤泡变异型乳头状癌最高(75.6%);组织学影响无进展生存(P = .014),但不是疾病特异性生存的显著预后因素。
要点
- 组织学类型与放射碘亲和力独立相关,Hürthle细胞癌亲和力最低。
- Hürthle细胞癌和滤泡状癌放射碘治疗后进展更常见。
- 组织学影响无进展生存,但不影响疾病特异性生存。
核心结论
- 分化型甲状腺癌组织学类型影响放射碘亲和力和无进展生存。
研究设计与样本
- 回顾性分析2001至2018年单中心因远处转移接受放射碘治疗的126例分化型甲状腺癌患者。
主要发现
- 放射碘亲和力与组织学类型独立相关(P < .001),与首次放射碘治疗时刺激后甲状腺球蛋白水平相关(P = .007)。
- 摄碘亲和力在Hürthle细胞癌最低(13.6%),经典型乳头状癌居中(21.4%),滤泡变异型乳头状癌(75.6%)和滤泡状癌(76.5%)最高。
- Hürthle细胞癌和滤泡状癌放射碘治疗后进展均显著多于滤泡变异型乳头状癌和经典型乳头状癌。
- 组织学类型影响无进展生存(P = .014),但不是疾病特异性生存的显著预后因素。
- 诊断时年龄、切除状态和首次放射碘治疗时刺激后甲状腺球蛋白与疾病特异性生存显著相关。
临床怎么用
- 对分化型甲状腺癌远处转移患者应结合组织学类型评估放射碘治疗获益可能性。
局限性
- 回顾性单中心设计,样本量有限(126例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The recommendations for radioactive-iodine treatment (RAIT) in metastatic differentiated thyroid cancer (DTC) are mostly based in the experience with papillary histotype and do not consider the differences within the distinct types of DTC, in terms of RAIT uptake and response. OBJECTIVE: This work aims to investigate the association between histology and RAIT avidity and response, and to evaluate whether histotype was an independent prognostic factor in progression-free survival (PFS) and disease-specific survival (DSS) after RAIT for distant metastatic disease. METHODS: A retrospective analysis was conducted of all DTC patients who underwent RAIT for distant metastatic disease, from 2001 to 2018, at a thyroid cancer referral center. We included 126 patients: 42 (33.3%) classical variant papillary thyroid cancer (cvPTC), 45 (35.7%) follicular variant PTC (fvPTC), 17 (13.5%) follicular thyroid cancer (FTC) and 22 (17.5%) Hürthle cell carcinoma. Main outcome measures included RAIT avidity and response. RESULTS: RAIT avidity was independently associated with histology (P < .001) and stimulated thyroglobulin (Tg) at first RAIT for distant lesions (P = .007). Avidity was lowest in HCC (13.6%), intermediate in cvPTC (21.4%), and highest in fvPTC (75.6%) and FTC (76.5%). Regarding RAIT response, HCC and FTC were not different; both showed significantly more often progression after RAIT than fvPTC and cvPTC. Histology influenced PFS (P = .014), but tumor type was not a significant prognostic factor in DSS. Instead, age at diagnosis, resection status, and stimulated Tg at the first RAIT were significantly associated with DSS. CONCLUSION: DTC histotype influenced RAIT avidity and PFS. It is crucial to better detect the metastatic patients that may benefit the most from RAIT.
引用
- Simões-Pereira J, Mourinho N, Ferreira TC, et al. Avidity and Outcomes of Radioiodine Therapy for Distant Metastasis of Distinct Types of Differentiated Thyroid Cancer. J Clin Endocrinol Metab. 2021. PMID: 34134139. doi:10.1210/clinem/dgab436
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。